These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38834219)

  • 21. The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis.
    Basendwh MA; Alharbi AA; Bukhamsin SA; Abdulwahab RA; Alaboud SA
    PLoS One; 2024; 19(5):e0298155. PubMed ID: 38814916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials.
    Hebert A; Thiboutot D; Stein Gold L; Cartwright M; Gerloni M; Fragasso E; Mazzetti A
    JAMA Dermatol; 2020 Jun; 156(6):621-630. PubMed ID: 32320027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clascoterone cream (1%) topical androgen receptor inhibitor for the treatment of acne in patients 12 years and older.
    Gold M
    Expert Rev Clin Immunol; 2021 Apr; 17(4):301-308. PubMed ID: 33616473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tazarotene 0.045% Lotion for the Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris in Adult Males.
    Cook-Bolden FE; Gold MH; Guenin E
    J Drugs Dermatol; 2020 Jan; 19(1):78-85. PubMed ID: 32023013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne Vulgaris.
    Eichenfield LF; Hebert AA; Gold LS; Cartwright M; Moro L; Han J; Squittieri N; Mazzetti A
    J Drugs Dermatol; 2023 Aug; 22(8):810-816. PubMed ID: 37556524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term use of spironolactone for acne in women: A case series of 403 patients.
    Garg V; Choi JK; James WD; Barbieri JS
    J Am Acad Dermatol; 2021 May; 84(5):1348-1355. PubMed ID: 33434594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cortexolone 17α-propionate (Clascoterone) Is a Novel Androgen Receptor Antagonist that Inhibits Production of Lipids and Inflammatory Cytokines from Sebocytes In Vitro.
    Rosette C; Agan FJ; Mazzetti A; Moro L; Gerloni M
    J Drugs Dermatol; 2019 May; 18(5):412-418. PubMed ID: 31141847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clascoterone cream (Winlevi) for acne.
    Med Lett Drugs Ther; 2021 Dec; 63(1640):202-204. PubMed ID: 35100239
    [No Abstract]   [Full Text] [Related]  

  • 29. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the Acne Treatment Paradigm.
    Purvis CG; Balogh EA; Feldman SR
    Ann Pharmacother; 2021 Oct; 55(10):1297-1299. PubMed ID: 33543640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review.
    Layton AM; Eady EA; Whitehouse H; Del Rosso JQ; Fedorowicz Z; van Zuuren EJ
    Am J Clin Dermatol; 2017 Apr; 18(2):169-191. PubMed ID: 28155090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating Acne in Adult Women.
    Harper JC; Stein Gold LF; Alexis AF; Tan JKL
    Semin Cutan Med Surg; 2018 Jun; 37(3S):S67-S70. PubMed ID: 30192345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contraceptive use in acne.
    Lam C; Zaenglein AL
    Clin Dermatol; 2014; 32(4):502-15. PubMed ID: 25017461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone and topical retinoids in adult female cyclical acne.
    Lessner E; Fisher S; Kobraei K; Osleber M; Lessner R; Elliott L; Wesson S
    J Drugs Dermatol; 2014 Feb; 13(2):126-9. PubMed ID: 24509960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of systemic agents in the treatment of acne vulgaris.
    Johnson BA; Nunley JR
    Am Fam Physician; 2000 Oct; 62(8):1823-30, 1835-6. PubMed ID: 11057839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clascoterone: First Approval.
    Dhillon S
    Drugs; 2020 Nov; 80(16):1745-1750. PubMed ID: 33030710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical considerations in acne treatment and the clinical impact of topical combination therapy.
    Krakowski AC; Stendardo S; Eichenfield LF
    Pediatr Dermatol; 2008 Jun; 25 Suppl 1():1-14. PubMed ID: 18494684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acne vulgaris: pathogenesis and therapeutic approach.
    Federman DG; Kirsner RS
    Am J Manag Care; 2000 Jan; 6(1):78-87; quiz 88-9. PubMed ID: 11009749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of Acne in Pregnancy.
    Chien AL; Qi J; Rainer B; Sachs DL; Helfrich YR
    J Am Board Fam Med; 2016; 29(2):254-62. PubMed ID: 26957383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerability and Efficacy of Clindamycin/Tretinoin versus Adapalene/Benzoyl Peroxide in the Treatment of Acne Vulgaris.
    Aschoff R; Möller S; Haase R; Kuske M
    J Drugs Dermatol; 2021 Mar; 20(3):295-301. PubMed ID: 33683070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.